|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PIK3CA was amplified in 70% of squamous carcinomas, 38% of large cell carcinomas, 19% of adenocarcinomas, and 67% of small cell lung cancers.
|
15317667 |
2004 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transformed SCC acquired genomic alterations related to the PI3K/AKT/mTOR pathway, in addition to the initial EGFR mutation.
|
31319998 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two novel oncogenes, namely squamous cell carcinoma (SCC)-related oncogene (SCCRO) and PIK3CA (gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide), have been identified as targets of 3q26.3 amplification.
|
12796399 |
2003 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway.
|
31302247 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This prompts us to pursue 3q26 (or PIK3CA) prognostic evaluation in a larger population of head and neck squamous cell carcinomas.
|
11358835 |
2001 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K inhibitors such as PI-103, PI-828 and PX-866 may be developed as potential therapeutic agents for effective treatment of oral squamous cell carcinoma (OSCC) patients, associated with activated PI3K/Akt pathway.
|
30519710 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
|
27923688 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
|
21824802 |
2011 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
KRAS and EGFR mutations were significantly more frequent in adenocarcinomas: PIK3CA in squamous cell carcinomas.
|
29186353 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activated pathway in lung ADC and SCC mainly focuses on MAPK and PI3K with different key genes of each, respectively, and the activated pathway of SCLC mainly focuses on JAK-STAT pathway.
|
27845189 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have studied the prognostic importance of PIK3CA mutations as well as the relation to other markers in a large number of early stage lung cancers of squamous carcinoma subtype.
|
28024696 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While 23 % of SCC tumors harbored a PIK3CA mutation, all BSCC cases were wild-type for PIK3CA (p = 0.002), and there were no differences in p53 expression between BSCCs and SCCs (p = 0.57), as assessed by immunohistochemistry.
|
25691283 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore screened 61 non-melanoma skin cancer samples (30 SCC and 31 BCC) for the presence of activating PIK3CA and AKT1 mutations.
|
20557351 |
2010 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activity of the downstream PI3K effector protein kinase B (PKB) was higher in SqCas than in AdCas and was correlated with PIK3CA copy number (r = 0.75), suggesting that these copy number increases contribute to activation of PI3K signaling in SqCas of the lung.
|
12097266 |
2002 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
|
18097548 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA amplifications in large cell and squamous cell carcinomas were significantly higher compared with adenocarcinomas.
|
23335533 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway.
|
31737114 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma.
|
16788758 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations were more common in squamous cell carcinomas than in non-squamous cell tumors (15.3% vs 7.3%, of P < 0.01).
|
26358014 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTEN (16.1%), STK11 (8.3%), and PIK3CA (7.2%) were the three most frequently enriched genes in smokers with SCC.
|
22768234 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations occurred more frequently in SCC than AC (25% vs. 11%, P=0.025), whereas KRAS mutations occurred more frequently in AC than SCC (24% vs. 3%, P<0.001) and ASC (24% vs. 3%, P<0.001).
|
26197069 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.
|
21110697 |
2011 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
|
24224046 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of PIK3CA was increased in OSCC tumors; however, none of the nine tested SNPs of PIK3CA was associated with susceptibility to OSCC in the studied population.
|
26722541 |
2015 |